Posted by Michael Wonder on 15 Feb 2025
European Commission approves CSL and Arcturus Therapeutics’ Kostaive, the first self-amplifying mRNA COVID-19 vaccine
14 February 2025 - Kostaive represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials.
CSL and Arcturus Therapeutics today announced that the European Commission has granted marketing authorisation for Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older.
